Regeneron Pharmaceuticals Stock Fair Value Calculator – Cowen Upgrades Regeneron to Outperform, Cites Long-Term Potential of Eylea Therapy for Eye Disease.

Trending News 🌥️

Regeneron Pharmaceuticals Stock Fair Value Calculator – Regeneron Pharmaceuticals ($NASDAQ:REGN) is a leading biotechnology company based in the United States that specializes in developing and commercializing innovative medicines for the treatment of serious medical conditions. The firm’s flagship product is the eye disease therapy Eylea, which is marketed with Bayer AG. The stock of Regeneron has recently received an upgrade from Cowen to Outperform from Market Perform ahead of the start of trading on Monday. This upgrade sent shares of the biotech firm higher in the pre-market due to the long-term prospects of the eye disease therapy Eylea. In September, Regeneron announced that a high-dose version of the highly successful therapy was found to be noninferior to the standard 2mg dose with less frequent administration. According to Tyler Van Buren, analyst at Cowen, the high dose data has “altered the trajectory” of Regeneron, and he raised his price target to $875 from $775 per share. The data from this study is encouraging as it could potentially lead to more efficacious outcomes with fewer treatments. This could result in reduced side effects and greater convenience for patients.

In addition, Regeneron also has several other promising therapies in its pipeline, which could further drive its share price higher in the long term. These include treatments for pain, cancer, and autoimmune diseases. With its strong pipeline and promising results for Eylea, it appears that Regeneron could be a sound investment for the long term. Investors should keep an eye on the company’s progress and consider adding shares to their portfolio if the stock looks attractive.

Share Price

On Monday, Cowen upgraded Regeneron Pharmaceuticals to Outperform citing the long-term potential of Eylea therapy for eye disease. So far the news has been mostly positive. At the end of the trading day, Regeneron’s stock opened at $749.0 and closed at $736.5, down by 0.9% from the previous closing price of $742.8. This dip in share price may have been due to investors wanting to wait for further information before committing to a position in the company. Eylea is a drug used for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema secondary to retinal vein occlusion.

The investment research firm believes that the drug still has a lot of room to grow and will become a key part of Regeneron’s portfolio in the future. The success of Eylea has been a major contributor to Regeneron’s success as a company, and its potential for further growth makes it an attractive investment opportunity. Investors should watch the stock closely to see how it performs in the coming weeks and months. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Regeneron Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Regeneron Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Regeneron Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Regeneron Pharmaceuticals are shown below. More…

VI Analysis – Regeneron Pharmaceuticals Stock Fair Value Calculator

Regeneron Pharmaceuticals’ long-term potential can be effectively analyzed with the help of the VI app. This app reflects the company’s fundamentals and provides insight into its future prospects. According to the data collected by our proprietary VI Line, the fair value of REGENERON PHARMACEUTICALS share is around $687.1. Thus, it is recommended to investors that they should be careful while investing in the stock of this company. Although the stock seems to be a good investment at the moment, investors should be aware of its underlying fundamentals to make prudent decisions. In conclusion, Regeneron Pharmaceuticals has a long-term potential and the VI app can be useful in analyzing its fundamentals. However, investors should take into account the fair value of its stock before investing to ensure that they make an informed decision. More…

VI Peers

The company’s competitors include Cue Biopharma Inc, CytoDyn Inc, and Belite Bio Inc.

– Cue Biopharma Inc ($NASDAQ:CUE)

The company’s market cap is $94.12M and its ROE is -48.38%. Cue Biopharma is a clinical-stage biopharmaceutical company that uses its proprietary technology to develop immuno-oncology and immuno-inflammation therapeutics. The company’s immuno-oncology product candidates are designed to target cancer cells and tumor-associated antigens. The company’s immuno-inflammation product candidates are designed to target pro-inflammatory cytokines.

– CytoDyn Inc ($OTCPK:CYDY)

CytoDyn Inc is a clinical stage biotechnology company. The company is focused on the development and commercialization of novel therapies for treating autoimmune diseases, cancer, and human immunodeficiency virus. CytoDyn’s lead product candidate is leronlimab, a monoclonal antibody that inhibits the CCR5 receptor.

Summary

Regeneron Pharmaceuticals has been receiving positive attention from investors and analysts due to its potential for long-term growth. Cowen recently upgraded the company to an “Outperform” rating, citing the potential of its Eylea therapy for treating eye diseases. Regeneron is a biopharmaceutical company that develops, manufactures, and commercializes medicines for treating serious medical conditions, including cancer, inflammatory, and cardiovascular diseases.

The company’s products have been approved by the FDA and are currently being used to treat various medical conditions. Investors are optimistic about the company’s future prospects and believe it has the potential to deliver strong returns over the long term.